Medipak Limited
Manufacturer Holds a DRAP Drug Manufacturing Licence (DML) for its products. Source: DRAP.
Pharmaceutical and medical-device manufacturer · Lahore · Pakistan
Lahore-based manufacturer established in 1982, producing infusion solutions, IV sets, medical devices, ophthalmic products, solid dosage forms and injectables.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Company type
- Pharmaceutical and medical-device manufacturer
- Address
- 132/1, Quaid-e-Azam Industrial Estate, Kot Lakhpat, Lahore 54700, Pakistan · 54700
- Website
- medipakpharma.com ↗
- Phone
- +92 42 111 017 017
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 100%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Agranil | Clopidogrel | 75 mg | Tablet | 10's | 052870 | PKR 271.80 | PKR 27.18/tablet | Near median |
| Agranil | Clopidogrel + Aspirin | 75 mg + 75 mg | Tablet | 10’s | 067975 | PKR 289.39 | PKR 28.94/tablet | Near median |
| Agranil Plus | Clopidogrel + Aspirin | 75 mg + 75 mg | Tablet | 10’s | 067975 | PKR 289.39 | PKR 28.94/tablet | Near median |
| Alten | Loratadine | 10 mg | Tablet | 1x10’s | 040743 | PKR 139.78 | PKR 13.98/tablet | Near median |
| Aqua | Water for Injection | 100 mL | Injection | 100ml | 106342 | PKR 87.04 | PKR 0.87/mL | 113% above median |
| Aqua | Water for Injection | 100 mL | Injection | 1000ml | 106345 | PKR 142.57 | PKR 0.14/mL | 65% below median |
| Aqua | Water for Injection | 100 mL | Injection | 100ml | 106357 | PKR 87.04 | PKR 0.87/mL | 113% above median |
| Aqua | Water for Injection | 100 mL | Injection | 1000ml | 106363 | PKR 142.57 | PKR 0.14/mL | 65% below median |
| Aqua Sterile | Water for Injection | 100 mL | Injection | 250ml | 106343 | PKR 102.04 | PKR 0.41/mL | Near median |
| Aqua Sterile | Water for Injection | 100 mL/100 mL | Injection | 500ml | 106344 | PKR 118.56 | PKR 0.24/mL | Near median |
| Aqua Sterile | Water for Injection | 100 mL | Injection | 250ml | 106361 | PKR 102.04 | PKR 0.41/mL | Near median |
| Aqua Sterile | Water for Injection | 100 mL/100 mL | Injection | 500ml | 106362 | PKR 118.55 | PKR 0.24/mL | Near median |
| Babilyte®Source observed | Sodium chloride | 3.50 g | Solution | 500ml | 015634Official source ↗ | No indexed price | — | — |
| Ciprofena | Ciprofloxacin | 3 mg/mL | Ophthalmic drops | 5ml | 022583 | PKR 213.22 | PKR 42.64/mL | Near median |
| Ciprofena | Ciprofloxacin | 500 mg | Tablet | 10's | 052867 | PKR 417.43 | PKR 41.74/tablet | Near median |
| Ciprofena | Ciprofloxacin | 250 mg | Tablet | 10's | 052877 | PKR 252.40 | PKR 25.24/tablet | Near median |
| Ciprofena | Ciprofloxacin | 400 mg/100 mL | IV infusion | 100ml | 067977 | PKR 327.06 | PKR 3.27/mL | Near median |
| Ciprofena | Ciprofloxacin | 200 mg/100 mL | IV infusion | 100ml | 067980 | PKR 232.98 | PKR 2.33/mL | Near median |
| Ciprofena | Ciprofloxacin | 200 mg | IV infusion | 100ml | 085217 | PKR 232.98 | PKR 2.33/mL | 9% above median |
| Ciprofena | Ciprofloxacin | 200 mg | IV infusion | 100ml | 087868 | PKR 232.98 | PKR 2.33/mL | 9% above median |
| Dextrose & Sodium Chloride | Dextrose + Sodium chloride | NaCl 0.45g + Dextrose 2.5g/100 mL | IV infusion | 500ml with set | 024013 | PKR 64.67 | — | No comparator |
| Diozide | Gliclazide | 80 mg | Tablet | 1x10’s | 040740 | PKR 176.68 | PKR 17.67/tablet | 69% above median |
| Epogen | Erythropoietin | 2000 IU | Injection | 100's | 043049 | PKR 197,673.34 | PKR 1,976.73/vial/unit | 5% below median |
| Epogen | Erythropoietin | 2000 IU | Injection | 1's | 043049 | PKR 2,090.70 | PKR 2,090.70/vial/unit | 6% above median |
| Epogen | Erythropoietin | 4000 IU | Injection | 100's | 043050 | PKR 364,710.95 | PKR 3,647.11/vial/unit | 8% below median |
| Epogen | Erythropoietin | 4000 IU | Injection | 1's | 043050 | PKR 3,964.25 | PKR 3,964.25/vial/unit | 9% above median |
| Epogen | Erythropoietin | 1000 IU/2 mL | Injection | 1's | 045718 | PKR 1,070.34 | PKR 1,070.34/vial/unit | No comparator |
| Epogen | Erythropoietin | 1000 IU | Injection | 1's | 045718 | PKR 1,070.34 | PKR 1,070.34/vial/unit | No comparator |
| Epogen | Erythropoietin | 10000 IU | IV injection | 100's | 059006 | PKR 813,816.44 | PKR 8,138.16/vial/unit | Near median |
| Epogen | Erythropoietin | 10000 IU | IV injection | 1's | 059006 | PKR 8,477.26 | PKR 8,477.26/vial/unit | Near median |
| Epogen | Erythropoietin | 20000 IU | IV injection | 100's | 062237 | PKR 1,367,666.07 | PKR 13,676.66/vial/unit | 8% below median |
| Epogen | Erythropoietin | 20000 IU | IV injection | 1's | 062237 | PKR 14,865.93 | PKR 14,865.93/vial/unit | 9% above median |
| Epogen | Erythropoietin | 40000 IU | IV injection | 100's | 062238 | PKR 1,415,237.89 | PKR 14,152.38/vial/unit | Near median |
| Epogen | Erythropoietin | 40000 IU | IV injection | 1's | 062238 | PKR 14,742.05 | PKR 14,742.05/vial/unit | Near median |
| Ezimax | Azithromycin | 250 mg | Tablet | 10's | 040739 | PKR 495.09 | PKR 49.51/tablet | 5% above median |
| GELA-STERIL Isotonic plasma substitute GELA-STERIL Isotonic plasma substituteSource observed | Polypeptide Degraded Gelatin… | 3 % | — | 500ml | 044750Official source ↗ | No indexed price | — | — |
| Gentamicin | Gentamicin | 80 mg | Injection | 2ml*10's | 014774 | PKR 459.84 | — | No comparator |
| Gentamicin | Gentamicin | 40 mg | Injection | 1ml x 3's | 014869 | PKR 75.68 | PKR 25.23/mL | 75% above median |
| Haemomed | Sodium chloride + Sodium acetate + Potassium chloride + Magnesium chloride + Calcium chloride + Dextrose | NaCl .887 + NaOAc .815 + KCl .358 + MgCl2·6H2O .164 + CaCl2·2H2O .353 + Dextrose .05247 kg/L | Hemodialysis concentrate | 4000ml | 009795 | PKR 743.30 | PKR 0.19/mL | No comparator |
| Haemomed Concentrate | Dextrose | 0.887 kg + 0.815 kg + 0.358 kg + 0.164 kg + 0.353 kg + 0.05247 kg / 1000 mL | Concentrate | 10000ml | 009795 | PKR 1,608.44 | PKR 0.16/mL | No comparator |
| Leovin | Levofloxacin | 250 mg | Tablet | 1x10’s | 052863 | PKR 485.38 | PKR 48.54/tablet | Near median |
| Leovin | Levofloxacin | 500 mg | Tablet | 10's | 052873 | PKR 807.67 | PKR 80.77/tablet | Near median |
| Leovin | Levofloxacin | 500 mg/100 mL | IV infusion | 100ml | 067974 | PKR 1,189.27 | PKR 11.89/mL | 145% above median |
| Loppimin | Simvastatin | 10 mg | Tablet | 1x10’s | 040742 | PKR 322.28 | PKR 32.23/tablet | 11% above median |
| Lozip | Omeprazole | 20 mg | Capsule | 14's | 023951 | PKR 252.40 | PKR 18.03/capsule | 9% below median |
| Medi-Oflox | Ofloxacin | 3 mg/mL | Ophthalmic drops | 5ml | 057406 | PKR 155.31 | PKR 31.06/mL | Near median |
| Medicarpine | Pilocarpine | 2% | Ophthalmic drops | 15ml | 010520 | PKR 223.27 | PKR 14.88/mL | 40% below median |
| Medicarpine | Pilocarpine | 2 % | Eye drops | 5ml | 010520 | PKR 172.46 | PKR 34.49/mL | No comparator |
| Medicarpine | Pilocarpine | 4 % | Eye drops | 10ml | 025424 | PKR 366.95 | PKR 36.70/mL | No comparator |
| Medigentacin | Gentamicin | 0.3 % | Eye drops | 5ml | 010884 | PKR 22.27 | PKR 4.45/mL | 83% above median |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.